US EditionPublished • loading... • Updated
Setback for More Alzheimer's Drugs Donanemab
Summary by Op-online.de
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
geoReposted by 
op-online.de
op-online.deExperts also do not see any additional benefits for the Alzheimer drug Donanemab compared to current older treatments.This could have consequences for the future availability of the drug.Further setbacks for hopefuls in the fight against Alzheimer's: Just like the active substance Lecanemab, in the opinion of a crucial expert body, Donanemab does not have any proven added value compared to older treatment approaches. This was reported by the Joi…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
